Efficacy and Safety of Vildagliptin as add-on Therapy to Metformin in Patients With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 183 participants.
Also called NCT01497522
- Study
- In this atlas
Overview
- Design
- Interventional study; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 183 participants
- Sponsor
- Registry
-
NCT01497522
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT01497522. Double masking; primary purpose treatment. Start 2011-12 (registry gives no type); primary completion 2013-02 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Vildagliptin as add-on Therapy to Metformin in Patients With Type 2 Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Vildagliptin
- Intervention (Drug)
- Placebo
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct01497522- Content hash
27b11cbea44f9989027d819ebedcb1c0ad2b0edaae462f556d62d4133152fdb0